Skip to main content
. 2009 Dec 31;5(4):153–166. doi: 10.3988/jcn.2009.5.4.153

Fig. 1.

Fig. 1

Two representative cases: magnetic resonance image (MRI, left column), FDG-PET (middle column) and PIB-PET (right column) of a normal control (top row) and an AD patient (bottom row). FDG: 2-[18F]fluoro-2-Deoxy-D-glucose, PIB: Pittsburgh Compound-B, AD: Alzheimer's disease.